


THEMIS MEDICARE LTD.						
Regd. Off Plot no 69A, GIDC Indl. Estate, Vapi- 396 195, Dist. Valsad, Gujarat.						
Corp. Office : 11/12, Udyog Nagar, S.V. Road, Goregoan (West), Mumbai-400 104						
AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31st MARCH, 2011						
(Rs in Lakhs)						
Particulars	STANDALONE FINANCIALS				CONSOLIDATED FINANCIALS	
	Quarter ended 31st March Audited		Year Ended 31st March Audited		Year Ended 31st March Audited	
	2011	2010	2011	2010	2011	2010
A] Sales / Income from Operations	3,340.12	5,065.02	23,971.02	21,855.54	25,622.05	23,460.99
Less : Excise Duty	25.06	149.70	594.21	624.91	594.21	624.91
1. (a) Net Sales/Income from operations	3,315.06	4,915.32	23,376.81	21,230.63	25,027.84	22,836.08
(b) Other Operating Income	12.32	19.72	188.67	100.98	188.67	100.98
(c) Total	3,327.39	4,935.04	23,565.48	21,331.61	25,216.51	22,937.06
2. Expenditure						
(a) (Increase)/Decrease in stock in trade and work-in-progress	(661.73)	157.31	(241.85)	163.29	(241.85)	163.30
(b) Consumption of raw materials	2,481.95	2,576.99	13,209.92	10,659.86	13,710.29	11,237.49
(c) Purchase of traded goods	39.28	27.79	877.99	580.67	877.99	580.67
(d) Employees Cost	508.76	439.46	1,975.08	1,764.55	1,975.08	1,764.55
(e) Depreciation	151.77	164.66	513.60	522.00	785.48	775.07
(f) Other Expenditure	1,373.29	1,392.40	5,737.45	5,257.68	6,425.39	5,863.13
(g) Total	3,893.31	4,758.61	22,072.19	18,948.05	23,532.38	20,384.21
(Any Item exceeding 10% of the total expenditure to be shown separately)						
3. Profit from Operations before Other Income, Interest & Exceptional Items(1-2)	(565.92)	176.43	1,493.29	2,383.56	1,684.13	2,552.85
4. Other Income	50.31	84.63	520.81	258.50	536.19	357.64
5. Profit/Loss before Interest and Exceptional Items(3+4)	(515.61)	261.06	2,014.10	2,642.06	2,220.32	2,910.49
6. Interest	271.17	250.50	1,031.60	935.09	1,030.73	935.84
7. Profit after Interest but before Exceptional Items (5-6)	(786.79)	10.56	982.50	1,706.97	1,189.59	1,974.65
8. Exchange Rate Difference - (Expense) / Income	(0.31)	(0.45)	40.90	82.45	40.90	82.45
9. Profit(+)/Loss(-) from Ordinary Activities before tax (7+8)	(787.09)	10.11	1,023.40	1,789.42	1,230.49	2,057.10
10. Tax Expense	(0.86)	(6.32)	(15.05)	(17.56)	207.43	(144.01)
11. Net profit(+)/Loss(-) from Ordinary Activities after tax (9-10)	(786.24)	16.43	1,038.45	1,806.98	1,023.06	2,201.11
12. Extra-ordinary Items(net of tax expense Rs. NIL)	(4.97)	58.82	(24.71)	59.52	(24.71)	5.70
13. Net Profit(+)/Loss(-) for the period (11+12)	(791.21)	75.25	1,013.74	1,866.50	998.35	2,195.41
14. Paid-up equity share capital - Face value of the share Rs. 10/-	805.05	805.05	805.05	805.05	805.05	805.05
15. Reserves excluding Revaluation Reserves as per Balance sheet of previous accounting year			8,089.27	7,075.53	8,578.81	7,580.46
16. Earnings per Share(EPS)						
(a) Basic and diluted EPS before Extra-ordinary items for the period, for the year to date and for the previous year (not to be annualized)	(9.83)	0.93	12.59	23.18	12.40	27.27
(b) Basic and diluted EPS after Extra-ordinary items for the period, for the year to date and for the previous year (not to be annualized)	(9.83)	0.93	12.59	23.18	12.40	27.27
17. Public Shareholding						
- No of shares			2,444,029	2,444,029		2,444,029
- Percentage of shareholding			30.36	30.36		30.36
18. Promoter & Promoter Group Shareholding						
(a) Pledged/encumbered						
(b) Non-encumbered						
No of Shares			5,606,471	5,606,471		5,606,471
% age share of total Promoter Holding			100	100	100.00	100.00
As % age of Total Share Capital			69.64	69.64		69.64
Notes :						
1. On Account of technical reasons, the Fourth Quarter Results were affected resulting in temporary reduction of Biotech Activity.						
2. The Company has only one segment namely pharmaceuticals, hence no separate disclosure of segmentwise information has been made.						
3. The above results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 03/05/2011 and have been audited by the Statutory Auditors.						
4. Statement of Assets and Liabilities as on 31st March 2011.						
5. The Board has recommended Dividend of Rs. 3/- per share (i.e., @ 30%) and Transfer to General Reserve of Rs 3 crores out of the profits of the Company						
6. Investment Complaint Status - Opening-0, Received-0, Resolved-0, Closing-0						
Particulars	STANDALONE RESULTS (AUDITED)		CONSOLIDATED RESULTS (AUDITED)			
	As at 31st Mar '11	As at 31st Mar '10	As at 31st Mar '11	As at 31st Mar '10		
SHARE HOLDERS FUNDS :						
(a) Capital	805.05	805.05	805.05	805.05		
(b) Reserves and Surplus	7,806.70	7,075.53	8,296.24	7,580.46		
LOAN FUNDS	9,755.75	9,262.73	12,330.17	12,353.06		
DEFERRED TAX LIABILITY	325.57	340.60	620.59	453.62		
TOTAL SOURCES OF FUNDS	18,693.07	17,484.91	22,052.05	21,192.19		
FIXED ASSETS	10,794.25	10,142.20	13,807.51	13,131.89		
INVESTMENTS	736.68	736.58	50.71	274.95		
CURRENT ASSETS, LOANS AND ADVANCES						
(a) Interest accrued on Investments	0.00	0.00	6.88	6.31		
(b) Inventories	3,859.14	3,616.14	4,555.93	4,244.17		
(c) Sundry Debtors	5,399.83	5,379.13	6,679.94	5,699.90		
(d) Cash and Bank balances	639.80	1,237.11	757.92	1,501.67		
(e) Loans and Advances	3,202.26	2,395.83	3,640.03	2,760.67		
Less :- Current Liabilities & Provisions						
(a) Liabilities	6,530.56	5,629.71	6,786.06	5,827.59		
(b) Provisions	398.33	392.17	560.81	595.78		
TOTAL APPLICATION OF FUNDS	18,693.07	17,484.91	22,052.05	21,192.19		
By order of the Board For: THEMIS MEDICARE LTD						
						
DR. DINESH PATEL (Managing Director & CEO)						
Place : Mumbai Date : 03/05/2011						